Vol. 2 No. 12 (2022)
Reimbursement Recommendations

Mepolizumab (Nucala)

Published December 2, 2022

Key Messages

  • CADTH recommends that Nucala should be reimbursed by public drug plans for the treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) if certain conditions are met.
  • Nucala should only be covered to treat adult patients with severe CRSwNP who have polyps on both sides of the nose, have already had at least 1 surgery to treat their nasal polyps or cannot have this type of surgery, and still have symptoms despite corticosteroid treatment for at least 3 months. When Nucala is first prescribed, physicians must submit a baseline Sino-nasal Outcome Test-22 (SNOT-22) score or endoscopy nasal polyp score so that response to treatment can be measured.
  • Nucala should only be reimbursed in patients whose nasal polyps are responding to treatment with Nucala and if it is prescribed by a physician with expertise in managing severe CRSwNP. The cost of Nucala must be lowered to be cost-effective and affordable.